1. Show article details.

    Novartis, Valeant bids herald new deal-making era for pharma

    Reuters – 5:55 PM ET 04/22/2014

    A series of agreed or proposed drug company deals may herald a new era of acquisitions not seen since last decade as pharmaceutical companies improve their best businesses and exit weaker ones. Novartis (NVS) and GlaxoSmithKline agreed to trade more than $20 billion worth of assets, boosting Novartis' (NVS) cancer-drug business and Glaxo's vaccines business.

  2. Show article details.

    Supreme Court Chief Justice Denies Teva's Request for an Injunction Relating to Generic Copaxone®; Clears Legal Hurdle for Mylan to Launch at Market Formation

    PR Newswire – 8:45 PM ET 04/18/2014

    PITTSBURGH, April 18, 2014 Mylan Inc. (MYL) today announced that Supreme Court Chief Justice Roberts has denied Teva's application for an injunction seeking to prevent Mylan's launch of a generic version of Copaxone® pending the Supreme Court's decision on Teva's appeal.

  3. Show article details.

    Supreme Court denies Teva stay in Copaxone patent fight

    Reuters – 4:16 PM ET 04/18/2014

    U.S. Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd (TEVA) that would have prevented a lower court ruling from going into effect while the court considers an appeal in a patent fight over Teva's top-selling multiple sclerosis drug Copaxone. The decision could help pave the way for generic competitors to go on the market as soon as next month.

  4. Show article details.

    U.S. top court denies Teva stay in Copaxone patent fight

    Reuters – 4:03 PM ET 04/18/2014

    U.S. Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd (TEVA) that would have prevented a lower court ruling from going into effect while the court considers an appeal in a patent fight over Teva's top-selling multiple sclerosis drug Copaxone. The decision could help pave the way for generic competitors to go on the market as soon as next month.

  5. Show article details.

    Teva willing to post bond to suspend decision on Copaxone

    Reuters – 3:50 PM ET 04/17/2014

    Teva Pharmaceutical Industries Ltd (TEVA) on Thursday told the U.S. Supreme Court that it is willing to post up to a $500 million bond in return for a decision suspending a lower court ruling that would allow generic competitors to go on the market as soon as next month.

  6. Show article details.

    Teva willing to post $500 million bond in Copaxone case

    Reuters – 3:18 PM ET 04/17/2014

    Teva Pharmaceutical Industries Ltd (TEVA) on Thursday told the U.S. Supreme Court that it is willing to post up to a $500 million bond in return for a decision suspending a lower court ruling that would allow generic competitors to go on the market as soon as next month.

  7. Show article details.

    Teva, Pfizer settle patent lawsuit over painkiller Celebrex

    Reuters – 9:18 AM ET 04/17/2014

    Teva Pharmaceutical Industries Ltd (TEVA) said it settled a patent litigation with Pfizer Inc (PFE), allowing the Israeli drugmaker to launch a generic version of Pfizer's blockbuster pain medication, Celebrex, in December. The news comes more than a month after a U.S. court invalidated a patent covering the drug, giving Pfizer's rivals, including Teva, a chance to sell cheaper versions of Celebrex.

  8. Show article details.

    Mylan Launches First Generic ORTHO EVRA® Patch

    PR Newswire – 4:13 PM ET 04/16/2014

    PITTSBURGH, April 16, 2014Mylan Inc. (MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched XULANE™, the generic version of Janssen Pharmaceuticals Inc.'s ORTHO EVRA®*. This product is indicated for the prevention of pregnancy in women who elect to use a transdermal patch as a method of contraception.

  9. Show article details.

    Mylan Announces Settlement Agreement for First-to-File Generess® Fe

    PR Newswire – 10:20 AM ET 04/15/2014

    PITTSBURGH, April 15, 2014Mylan Inc. (MYL) today confirmed that it and its partner Famy Care Ltd. have entered into a settlement and license agreement with Warner Chilcott Company, LLC, settling the parties' litigation in connection with Mylan's filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Norethindrone and Ethinyl Estradiol Chewable Tablets 0.8 mg/0.02...

  10. Show article details.

    Mylan Launches Generic Lunesta® Tablets

    PR Newswire – 10:08 AM ET 04/15/2014

    PITTSBURGH, April 15, 2014 Mylan Inc. (MYL) today announced that it has launched Eszopiclone Tablets 1 mg, 2 mg and 3 mg, the generic version of Sunovion Pharmaceuticals Inc.'s Lunesta®. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated for the treatment of insomnia.

  11. Show article details.

    Legal Updates, Stock Price Movements, New Awareness Campaigns, and Senior-level Appointments - Analyst Notes on Mylan, WellPoint, Forest, Novatis and Intercept

    PR Newswire – 8:00 AM ET 04/15/2014

    NEW YORK, April 15, 2014 Today, Analysts Review released its analysts' notes regarding Mylan Inc. (MYL), WellPoint Inc. (WLP), Forest Laboratories Inc. (FRX), Novatis AG and Intercept Pharmaceuticals Inc. (ICPT). Private wealth members receive these notes ahead of publication. SOURCE Analysts Review.

  12. Show article details.

    Prosonix and Mylan Enter Into Global Licensing Agreement for Generic Versions of Inhaled Respiratory Products Flixotide® and Flovent®

    PR Newswire – 8:00 AM ET 04/15/2014

    OXFORD, England and PITTSBURGH, April 15, 2014 Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, today announced that it has entered into a global licensing agreement with Mylan Inc. (MYL), one of the world's leading global pharmaceutical companies, for its leading inhaled respiratory products, PSX1001 and PSX1050.

  13. Show article details.

    U.S. healthcare usage and spending resumes rise in 2013 -report

    Reuters – 12:01 AM ET 04/15/2014

    Americans used more health services and spent more on prescription drugs in 2013, reversing a recent trend, though greater use of cheaper generic drugs helped control spending, according to a report issued on Tuesday by a leading healthcare information company. Spending on medicines rose 3.2 percent in the United States last year to $329.2 billion.

  14. Show article details.

    Generics file response to Teva in Copaxone patent fight

    Reuters – 5:48 PM ET 04/14/2014

    Generic drug manufacturers on Monday asked the U.S. Supreme Court to allow a lower court ruling favoring them to take effect while the high court considers an appeal in a patent fight over Teva Pharmaceutical Industries Ltd's (TEVA) top-selling multiple sclerosis drug, Copaxone.

  15. Show article details.

    Campaign for Wider Reach, Clinical Trial Results, Recognitions, Earnings Release Schedule, and Favorable Ruling - Analyst Notes on Cigna, Medtronic, WellPoint, Mylan, and Express Scripts

    PR Newswire – 8:00 AM ET 04/11/2014

    NEW YORK, April 11, 2014 Today, Analysts Review released its analysts' notes regarding Cigna Corp. (CI), Medtronic, Inc. (MDT), WellPoint Inc. (WLP), Mylan, Inc. (MYL), and Express Scripts Inc. (ESRX). Private wealth members receive these notes ahead of publication.

  16. Show article details.

    Federal Judge Enforces Settlement Agreement Between Mylan and Endo Regarding Generic FROVA®

    PR Newswire – 7:30 AM ET 04/11/2014

    PITTSBURGH, April 11, 2014Mylan Inc. (MYL) today confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Frovatriptan Succinate Tablets, 2.5 mg.

  17. Show article details.

    Pharma Equities under Review -- Research on Mylan, Actavis, Hospira, and Medicines

    PR Newswire – 12:30 PM ET 04/10/2014

    LONDON, April 10, 2014 On Wednesday, April 09, 2014, the NASDAQ Composite ended at 4,183.90, up 1.72%, the Dow Jones Industrial Average advanced 1.11% to 16,437.18, and the S&P 500 closed at 1,872.18, up 1.09%. The gains were broad based as eight out of 10 sectors ended the session in positive. SOURCE Investor-Edge.

  18. Show article details.

    Mylan Mistimes Its Overseas Adventure

    MarketWatch – 11:02 AM ET 04/09/2014

    Shares in Mylan, the U.S. specialty pharmaceutical company, jumped on reports it was eyeing a purchase of Meda AB (MDABF). It held onto most gains even after the Swedish company said it had rejected a proposal. Mylan's interest in Meda is understandable--it could join the list of U.S. pharmaceutical companies heading overseas to reduce their tax bill.

  19. Show article details.

    Mylan Schedules First Quarter 2014 Financial Results Conference Call and Live Webcast

    PR Newswire – 4:24 PM ET 04/08/2014

    PITTSBURGH, April 8, 2014Mylan Inc. (MYL) today announced that it will host a conference call and live webcast on Thursday, May 1, 2014, at 11 a.m. ET, to review the company's financial results for the first quarter ended March 31, 2014. Mylan will release its financial results on May 1, before the market opens.

  20. Show article details.

    U.S. justice requests generics respond in Copaxone litigation

    Reuters – 11:57 AM ET 04/08/2014

    U.S. Chief Justice John Roberts on Tuesday asked generic drug manufacturers to respond to a request from Teva Pharmaceutical Industries Ltd (TEVA) seeking to prevent a lower court ruling from taking effect while the high court considers an appeal in a patent fight over Teva's top-selling multiple sclerosis drug, Copaxone.

Page:

Today's and Upcoming Events

  • May
    1

    MYL to announce Q1 earnings Before Market (Confirmed)

  • May
    1

    MYL Earnings Conference Call at 11:00 AM Listen

Past Events (last 90 days)

  • Apr
    11

    Shareholders Meeting

Data provided by Wall Street Horizon, Inc. © 2014

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.